The Melanoma Research Foundation Breakthrough Consortium Partners with Biologics, Inc. in Launch of Premiere Trial
<0> Biologics, Inc.Allison Keenan, 919-459-4922 </0>
The Melanoma Research Foundation Breakthrough Consortium (MRFBC) has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAF mutation positive metastatic melanoma.
MRFBC has selected Biologics to be its sole distribution partner in overseeing the trial’s drug supply, patient-specific distribution, and accountability reporting. Biologics will also provide a customized quality assurance program to ensure randomization is upheld and to reduce waste.
The primary objective of the trial is to assess the progression-free survival of patients on bevacizumab and vemurafinib compared to patients treated with vemurafenib alone. Secondary objectives include assessing response rate and overall survival of patients. As the combination of vemurafenib and bevacizumab has not previously been investigated, this study will also evaluate the impact of bevacizumab on vemurafenib-induced toxicity. The goal is to enroll 180 patients who meet certain eligibility criteria.
“We’re thrilled to have the opportunity to support MRFBC in this important trial,” said Karl Buer, program lead for Biologics. “This study presents an exciting opportunity to enhance the effectiveness of an important therapy in one of the most treatment-resistant malignancies.”
Robyn Burns
The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma. Committed to the support of medical research in finding effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about prevention, diagnosis and the treatment of melanoma. The MRF is an active advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. The MRF's website is the premier source for melanoma information seekers.
The mission of the MRFBC is to accelerate the research and development of the most promising therapeutics in melanoma in order to deliver curative options to patients. To this end, the Consortium develops collaborative, multi-sector partnerships across the breadth of melanoma disciplines - basic, translational and clinical science - to expedite development of combinations of therapies as well as novel single agents; support pre-clinical research to facilitate rational combinations; create a virtual annotated specimen biorepository; and identify biomarkers that have prognostic and predictive value or value as a new therapeutic target.
Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. For more information, visit .